These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11685725)

  • 1. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
    Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
    J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
    Taplin ME; Bubley GJ; Rajeshkumar B; Shuster T; Ko YJ; Morganstern DE
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):32-9. PubMed ID: 11685726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005.
    Chang K; Qin XJ; Zhang HL; Dai B; Zhu Y; Shi GH; Shen YJ; Zhu YY; Ye DW
    Asian J Androl; 2016; 18(3):452-5. PubMed ID: 26323560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Nakabayashi M; Xie W; Buckle G; Bubley G; Ernstoff MS; Walsh W; Morganstern DE; Kantoff PW; Taplin ME
    Urology; 2013 Mar; 81(3):611-6. PubMed ID: 23452809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
    Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
    Tay MH; Kaufman DS; Regan MM; Leibowitz SB; George DJ; Febbo PG; Manola J; Smith MR; Kaplan ID; Kantoff PW; Oh WK
    Ann Oncol; 2004 Jun; 15(6):974-8. PubMed ID: 15151957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
    Oh WK; George DJ; Kaufman DS; Moss K; Smith MR; Richie JP; Kantoff PW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):40-4. PubMed ID: 11685727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
    Amato R; Stepankiw M; Gonzales P
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1629-34. PubMed ID: 23604530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
    Berry W; Dakhil S; Gregurich MA; Asmar L
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):8-15. PubMed ID: 11685723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
    Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
    J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.